Review | Published:

The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome

Leukemia volume 30, pages 18161823 (2016) | Download Citation

Abstract

Children with Down syndrome (DS) are at a 20-fold increased risk for acute lymphoblastic leukemia (DS-ALL). Although the etiology of this higher risk of developing leukemia remains largely unclear, the recent identification of CRLF2 (cytokine receptor like factor 2) and JAK2 mutations and study of the effect of trisomy of Hmgn1 and Dyrk1a (dual-specificity tyrosine phosphorylation-regulated kinase 1A) on B-cell development have shed significant new light on the disease process. Here we focus on the clinical features, biology and genetics of ALL in children with DS. We review the unique characteristics of DS-ALL on both the clinical and molecular levels and discuss the differences in treatments and outcomes in ALL in children with DS compared with those without DS. The identification of new biological insights is expected to pave the way for novel targeted therapies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , . Acute leukemias in children with Down syndrome. Mol Genet Metab 2012; 107: 25–30.

  2. 2.

    , , , . Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 2005; 44: 8–12.

  3. 3.

    , , , , , et al. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res 2009; 53: 419–425.

  4. 4.

    , , . Refractive error, binocular vision and accommodation of children with Down syndrome. Clin Exp Optom 2015; 98: 3–11.

  5. 5.

    , . Motor, linguistic, personal and social aspects of children with Down syndrome. J Appl Oral Sci 2015; 23: 424–430.

  6. 6.

    . The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512–524.

  7. 7.

    , , . Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165–169.

  8. 8.

    , , . Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019–1025.

  9. 9.

    , , . Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005; 217: 126–134.

  10. 10.

    , , , , , et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down qsyndrome. Nat Genet 2002; 32: 148–152.

  11. 11.

    , , . Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Rev Hematol 2014; 7: 831–840.

  12. 12.

    , , , , , et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012; 120: 3187–3205.

  13. 13.

    , , , , , et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: A Nationwide Prospective Study in Japan. Pediatr Blood Cancer 2016; 63: 248–254.

  14. 14.

    , , , , , et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005; 97: 226–231.

  15. 15.

    , , , , , et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010; 116: 1045–1050.

  16. 16.

    , , , , , et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128: 797–804.

  17. 17.

    , , , , , et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 2014; 123: 70–77.

  18. 18.

    , , , , , et al. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer 2008; 113: 515–521.

  19. 19.

    , , , , , et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002; 99: 245–251.

  20. 20.

    , , , , , et al. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukemia 2013; 27: 866–870.

  21. 21.

    , , , , , et al. Event free (EFS) and overall survival (OS) for children with Down syndrome (DS) and B-lymhoblastic leukemia in Children's Oncology Group (COG) trials AALL0232 and AALL0331. Pediatr Blood Cancer 2014; 61: S4; abstract no. 4009.

  22. 22.

    , , , , . Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010; 95: 1106–1113.

  23. 23.

    , , , , , et al. Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome. Pediatr Blood Cancer 2015; 62: 148–152.

  24. 24.

    , , , , , et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2014; 61: 1126–1128.

  25. 25.

    , , , , , et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517–528.

  26. 26.

    , , , . CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015; 125: 4017–4023.

  27. 27.

    , , , . Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 2016; 13: 25–40.

  28. 28.

    , , , , , et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507–1517.

  29. 29.

    , , , , , et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6, 224ra25.

  30. 30.

    , , , , , et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57–66.

  31. 31.

    , , , , , et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121: 5154–5157.

  32. 32.

    , . Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015; 6: 61–79.

  33. 33.

    , , , , , et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012; 120: 3510–3518.

  34. 34.

    , , , , , et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 2012; 120: 833–842.

  35. 35.

    , , , , , et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet 2014; 46: 618–623.

  36. 36.

    , , , , , et al. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med 2015; 212: 953–970.

  37. 37.

    , . Ikaros and leukaemia. Br J Haematol 2015; 169: 479–491.

  38. 38.

    , , , , , et al. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med 2013; 2: 412–419.

  39. 39.

    , , , , , et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012; 26: 2204–2211.

  40. 40.

    , , , , , et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009; 113: 646–648.

  41. 41.

    , , , , , et al. A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements. Biomarker Res 2015; 3: 11.

  42. 42.

    , , , , , et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 2011; 25: 1555–1563.

  43. 43.

    , , , , , et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006–1017.

  44. 44.

    . Similar yet different. Blood 2010; 116: 1019–1020.

  45. 45.

    , , , , , et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243–1246.

  46. 46.

    , , , , , et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688–2698.

  47. 47.

    , , , , , et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 252–257.

  48. 48.

    , . CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res 2010; 70: 7347–7352.

  49. 49.

    , , , , , et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005–1015.

  50. 50.

    , , , , , et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109: 2202–2204.

  51. 51.

    , , , , , et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484–1492.

  52. 52.

    , , , , , et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 930–932.

  53. 53.

    , . A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Bailliere's Best Pract Clin Haematol 2014; 27: 83–93.

  54. 54.

    , , , , . The molecular regulation of Janus kinase (JAK) activation. Biochem J 2014; 462: 1–13.

  55. 55.

    , , . Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 2010; 14: 504–527.

  56. 56.

    , , , , , et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011; 208: 901–908.

  57. 57.

    , , , , , et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun 2014; 5: 4654.

  58. 58.

    , , , , , et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 2008; 111: 767–775.

  59. 59.

    , , , , , et al. Increased dosage of the murine chromosome 21 orthog Dyrk1a promotes megakaryoblastic leukemia in Down syndrome. J Clin Invest 2012; 122: 948–962.

  60. 60.

    , , , , . Resolution and characterization of pro-B and pre–pro-B cell stages in normal mouse bone marrow. J Exp Med 1991; 173: 1213–1225.

  61. 61.

    , , , , , . Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3. EMBO J 2005; 24: 3038–3048.

  62. 62.

    , , , , , et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA 2012; 109: 17579–17584.

  63. 63.

    , , , . DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications. Pharmacol Ther 2015; 151: 87–98.

  64. 64.

    , , , , , . Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 2011; 138: 2543–2554.

  65. 65.

    , , , , , et al. Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging 2012; 33: 1389–1399.

  66. 66.

    , , , , , et al. DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease. Cell Death Dis 2014; 5: e1289.

  67. 67.

    , , , , , et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459: 1126–1130.

  68. 68.

    , , , , . DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011; 25: 801–813.

  69. 69.

    , , , , , . The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 2014; 13: 2084–2100.

  70. 70.

    , , , . Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol Cell 2013; 52: 87–100.

  71. 71.

    . The genomic landscape of acute lymphoblastic leukemia in children and young adults. Hematology 2014; 2014: 174–180.

  72. 72.

    , , , , , et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007; 109: 2327–2330.

  73. 73.

    , , , , , et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014; 508: 98–102.

  74. 74.

    , , , , , et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011; 117: 6848–6855.

  75. 75.

    , , , , , et al. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. Br J Haematol 2014; 165: 552–555.

  76. 76.

    , , , , , et al. Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries. J Hematol Oncol 2014; 7: 32.

  77. 77.

    , , , , , et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005; 106: 4043–4049.

Download references

Acknowledgements

This review was supported by grants from the National Institutes of Health (R01 CA101774, to JC), the Rally and Bear Necessities Foundations (to JC), the Unites States–Israel Binational Science Foundation (to SI and JC), the Samuel Waxman Cancer Research Foundation (to SI and JC), the Israel Science Foundation Legacy Program (to SI), the Israel Cancer Research Foundation (to SI) and Children with Cancer UK (to SI). This review is also supported, in part, by an Alpha Omega Alpha Carolyn L Kuckein Student Research Fellowship.

Author information

Author notes

    • P Lee
    •  & R Bhansali

    These authors contributed equally to this work.

Affiliations

  1. Division of Hematology/Oncology/Stem Cell Transplant, Ann and Robert H Lurie Children’s Hospital of Chicago, Chicago, IL, USA

    • P Lee
    •  & N Hijiya
  2. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    • R Bhansali
    •  & J D Crispino
  3. Edmond and Lily Safra, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel

    • S Izraeli
  4. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    • N Hijiya

Authors

  1. Search for P Lee in:

  2. Search for R Bhansali in:

  3. Search for S Izraeli in:

  4. Search for N Hijiya in:

  5. Search for J D Crispino in:

Competing interests

Dr Hijiya is a consultant for Novartis. The other authors declare no conflict of interest.

Corresponding authors

Correspondence to N Hijiya or J D Crispino.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2016.164

Further reading